The immune-status in patients with bone and soft-tissue sarcomas.
The immunologic status of 50 sarcoma patients was established. It was possible to apply the DNCB test and the recall antigen test in most cases during the course of the illness. The PHA stimulation of the lymphocytes and their cytotoxicity on homologous sarcoma cell lines were also correlated with the course of the illness. Nonspecific tests related neither to each other nor to the development of the illness while the tumor-specific cytotoxicity test correlated closely with the course of the disease.
D000293:Adolescent; D000328:Adult; D000941:Antigens; D001859:Bone Neoplasms / Q000276:immunology*; D002648:Child; D002813:Chondrosarcoma / Q000276:immunology; D003601:Cytotoxicity Tests, Immunologic; D004137:Dinitrochlorobenzene / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D037102:Lectins / Q000494:pharmacology; D008213:Lymphocyte Activation; D008297:Male; D012516:Osteosarcoma / Q000276:immunology; D011379:Prognosis; D012509:Sarcoma / Q000276:immunology*; D012512:Sarcoma, Ewing / Q000276:immunology; D012882:Skin Tests; D012983:Soft Tissue Neoplasms / Q000276:immunology*
D000941:Antigens; D004137:Dinitrochlorobenzene; D037102:Lectins